Wearable devices, ischemic heart disease and cardiovascular outcomes: A systematic review and meta-analysis

IF 3.9 2区医学 Q2 GERIATRICS & GERONTOLOGY

Maturitas Pub Date : 2025-02-01 DOI:10.1016/j.maturitas.2024.108186

Julia M.A. Ballavenuto, Nisachon Tongtip, Nina L.S. Fischer, Marco Bardus

{"title":"Wearable devices, ischemic heart disease and cardiovascular outcomes: A systematic review and meta-analysis","authors":"Julia M.A. Ballavenuto, Nisachon Tongtip, Nina L.S. Fischer, Marco Bardus","doi":"10.1016/j.maturitas.2024.108186","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>To evaluate the impact of wearable devices when associated with usual care on the incidence of major adverse cardiovascular events (MACE) in patients with ischemic heart disease compared with usual care alone.</div></div><div><h3>Methods</h3><div>Randomised clinical trials with patients aged 18 years and above with ischemic heart disease, using wearable devices and assessing at least one of the primary outcomes (myocardial infarction, stroke, cardiovascular mortality, or major adverse cardiovascular events) or secondary outcomes (all-cause mortality, hospitalisation, all arrhythmias, heart failure, unstable angina or revascularisation procedures) were included. MEDLINE, EMBASE, Cochrane Library, CINHAL, INAHTA and the Web of Science Core Collection were searched in April 2024. Studies were also identified via citation searching. Cochrane Risk of Bias version 1 was applied as provided in Covidence. Meta-analyses were performed when possible.</div></div><div><h3>Results</h3><div>Six studies of moderate quality were included. Wearables showed positive effects in reducing major adverse cardiovascular events (RR 0.75, 95 % CI 0.57–0.98, two studies) and all-cause mortality (RR 0.64, 95 % CI 0.43–0.96, three studies); no significant effects were found on myocardial infarction (RR 0.89, 95 % CI 0.59–1.34, four studies), cardiovascular mortality (RR 0.35, 95 % CI 0.07–1.73, three studies), hospitalisations (RR 0.77, 95 % CI 0.56–1.07, five studies), all arrhythmias (RR 1.10, 95 % CI 0.49–2.48, two studies), and heart failure (RR 0.85, 95 % CI 0.61–1.18, two studies). Meta-analysis could not be performed for stroke, unstable angina, and revascularisation procedures. Grading of Recommendations Assessment, Development and Evaluation (GRADE) certainty of evidence was deemed low or very low.</div></div><div><h3>Discussion</h3><div>While wearables seem to have some positive effects for patients with ischemic heart disease, only weak recommendations for use are possible. More large-scale, high-quality randomised clinical trials are needed to recommend the routine use of wearables in combination with usual care.</div></div><div><h3>Protocol registration on PROSPERO</h3><div>CRD42024586137</div></div>","PeriodicalId":51120,"journal":{"name":"Maturitas","volume":"193 ","pages":"Article 108186"},"PeriodicalIF":3.9000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Maturitas","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0378512224002810","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GERIATRICS & GERONTOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

To evaluate the impact of wearable devices when associated with usual care on the incidence of major adverse cardiovascular events (MACE) in patients with ischemic heart disease compared with usual care alone.

Methods

Randomised clinical trials with patients aged 18 years and above with ischemic heart disease, using wearable devices and assessing at least one of the primary outcomes (myocardial infarction, stroke, cardiovascular mortality, or major adverse cardiovascular events) or secondary outcomes (all-cause mortality, hospitalisation, all arrhythmias, heart failure, unstable angina or revascularisation procedures) were included. MEDLINE, EMBASE, Cochrane Library, CINHAL, INAHTA and the Web of Science Core Collection were searched in April 2024. Studies were also identified via citation searching. Cochrane Risk of Bias version 1 was applied as provided in Covidence. Meta-analyses were performed when possible.

Results

Six studies of moderate quality were included. Wearables showed positive effects in reducing major adverse cardiovascular events (RR 0.75, 95 % CI 0.57–0.98, two studies) and all-cause mortality (RR 0.64, 95 % CI 0.43–0.96, three studies); no significant effects were found on myocardial infarction (RR 0.89, 95 % CI 0.59–1.34, four studies), cardiovascular mortality (RR 0.35, 95 % CI 0.07–1.73, three studies), hospitalisations (RR 0.77, 95 % CI 0.56–1.07, five studies), all arrhythmias (RR 1.10, 95 % CI 0.49–2.48, two studies), and heart failure (RR 0.85, 95 % CI 0.61–1.18, two studies). Meta-analysis could not be performed for stroke, unstable angina, and revascularisation procedures. Grading of Recommendations Assessment, Development and Evaluation (GRADE) certainty of evidence was deemed low or very low.

Discussion

While wearables seem to have some positive effects for patients with ischemic heart disease, only weak recommendations for use are possible. More large-scale, high-quality randomised clinical trials are needed to recommend the routine use of wearables in combination with usual care.

Protocol registration on PROSPERO

CRD42024586137

查看原文本刊更多论文

可穿戴设备、缺血性心脏病和心血管后果：系统回顾与荟萃分析。

目的：评价与常规护理相结合的可穿戴设备对缺血性心脏病患者主要不良心血管事件（MACE）发生率的影响。方法：纳入18岁及以上缺血性心脏病患者的随机临床试验，使用可穿戴设备，评估至少一项主要结局（心肌梗死、中风、心血管死亡率或主要不良心血管事件）或次要结局（全因死亡率、住院、所有心律失常、心力衰竭、不稳定型心绞痛或血运重建手术）。2024年4月检索MEDLINE、EMBASE、Cochrane Library、CINHAL、INAHTA和Web of Science Core Collection。研究也通过引文检索确定。采用Cochrane Risk of Bias version 1，参考《covid》。在可能的情况下进行meta分析。结果：纳入了6项中等质量的研究。可穿戴设备在减少主要不良心血管事件（RR = 0.75, 95% CI = 0.57-0.98, 2项研究）和全因死亡率（RR = 0.64, 95% CI = 0.43-0.96, 3项研究）方面显示出积极作用；在心肌梗死（RR 0.89, 95% CI 0.59-1.34, 4项研究）、心血管死亡率（RR 0.35, 95% CI 0.07-1.73, 3项研究）、住院（RR 0.77, 95% CI 0.56-1.07, 5项研究）、所有心律失常（RR 1.10, 95% CI 0.49-2.48, 2项研究）和心力衰竭（RR 0.85, 95% CI 0.61-1.18, 2项研究）方面未发现显著影响。不能对中风、不稳定型心绞痛和血运重建手术进行meta分析。评价、发展和评价（GRADE）证据的确定性被认为是低或非常低。讨论：虽然可穿戴设备似乎对缺血性心脏病患者有一些积极的影响，但只有微弱的使用建议是可能的。需要更多大规模、高质量的随机临床试验来推荐将可穿戴设备与常规护理相结合的常规使用。普洛斯佩罗协议注册：CRD42024586137。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Maturitas 医学-妇产科学

CiteScore

9.10

自引率

2.00%

发文量

142

审稿时长

40 days

期刊介绍： Maturitas is an international multidisciplinary peer reviewed scientific journal of midlife health and beyond publishing original research, reviews, consensus statements and guidelines, and mini-reviews. The journal provides a forum for all aspects of postreproductive health in both genders ranging from basic science to health and social care. Topic areas include:• Aging• Alternative and Complementary medicines• Arthritis and Bone Health• Cancer• Cardiovascular Health• Cognitive and Physical Functioning• Epidemiology, health and social care• Gynecology/ Reproductive Endocrinology• Nutrition/ Obesity Diabetes/ Metabolic Syndrome• Menopause, Ovarian Aging• Mental Health• Pharmacology• Sexuality• Quality of Life